

GENENT.065A



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT

TECH CENTER 1600/2900

APR 24 2002

RECEIVED

#22/E
Dmt
4-25-02

Applicant : De Sauvage et al.

Appl. No. : 09/272,835

Filed : March 19, 1999

For : GFRALPHA3 AND ITS USES

Examiner : Hayes, R.

Group Art Unit 1647

I hereby certify that this correspondence and all marked attachments are being deposited via Federal Express in an envelope addressed to: United States Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington VA 22202, on

April 18, 2002

(Date)

Ginger R. Dreger, Reg. No. 33,055

AMENDMENT

United States Patent and Trademark Office
Box Sequence, Room 1B03-Mailroom
Crystal Plaza Two, 2011 South Clark Place
Arlington VA 22202

Dear Sir:

In response to the Office Action and Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures mailed on April 9, 2002 (Paper No. 21), setting a one month term, Applicants hereby request the entry of the substitute "Sequence Listing" submitted concurrently herewith into the specification, starting on a new page, immediately following the claims, and of the following amendments to the specification. The present substitute Sequence Listing serves to replace the substitute Sequence Listing mailed on November 8, 2001.

In the Specification:

/ Please replace the paragraph beginning at page 49, line 9, with the following amended paragraph:

E) --The deduced amino acid sequence (SEQ ID NO: 17) of DNA48614 and comparison to SEQ ID NO: 15, revealed it to be an alternatively spliced form of DNA48613, with a 30 amino acid deletion (amino acid positions 127-157, counting from the initiation methionine), as shown